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Epitope speciﬁcityUnderstanding natural immunologic control over Human Immunodeﬁciency Virus (HIV)-1 replication, as occurs
in rare long-term nonprogressors/elite controllers (LTNP/EC), should inform the design of efﬁcacious HIV vac-
cines and immunotherapies. Durable control in LTNP/EC is likely mediated by highly functional virus-speciﬁc
CD8+ T-cells. Protective Human Leukocyte Antigen (HLA) class I alleles, like B*27 and B*57, are present in
most, but not all LTNP/EC, providing an opportunity to investigate features shared by their HIV-speciﬁc immune
responses. To better understand the contribution of epitope targeting and conservation to immune control, we
compared the CD8+ T-cell speciﬁcity and function of B*27/57neg LTNP/EC (n = 23), B*27/57pos LTNP/EC (n =
23) and B*27/57neg progressors (n=13). Finemapping revealed 11 previously unreported immunodominant re-
sponses. Although B*27/57neg LTNP/EC did not targetmore highly conserved epitopes, their CD8+ T-cell cytotoxic
capacity was signiﬁcantly higher than progressors. Similar to B*27/57pos LTNP/EC, this superior cytotoxicity was
mediated by preferential expansion of immunodominant responses and lysis through the predicted HLA. These
ﬁndings suggest that increased CD8+ T-cell cytotoxic capacity is a common mechanism of control in most
LTNP/EC regardless of HLA type. They also suggest that potent cytotoxicity can be mediated through various
epitopes and HLA molecules and could, in theory, be induced in most people.
Published by Elsevier B.V.1. Introduction
Investigations performed in long-term nonprogressors/elite
controllers (LTNP/EC) have provided considerable insights into the
mechanisms underlying durable control over HIV replication. Strong
associations have been identiﬁed between this phenotype and particular
Major Histocompatibility Complex (MHC) class I alleles, especially B*27
and B*57 (Kaslow et al., 1996; Migueles and Connors, 2010; Migueles
et al., 2000). A similar phenotype has been found in Simian Immunodeﬁ-
ciency Virus (SIV)-infected Rhesus macaques and is associated with
Mamu B*8 and B*17 (Loffredo et al., 2007; Yant et al., 2006).ity Section, Laboratory of
ectious Diseases, NIH, Building
SA.
).It has been suggested that these protective alleles mediate their
effect by presenting peptides whose sequences are conserved due to
structural or functional constraints on the virus (Allen et al., 2005;
Brockman et al., 2007; Crawford et al., 2007; Friedrich et al., 2004;
Goulder et al., 1997; Leslie et al., 2004; Pereyra et al., 2014; Peyerl
et al., 2004). In some studies of progressors, focused targeting by
HIV-speciﬁc CD8+ T-cell responses of more conserved regions has
been associated with lower HIV RNA levels (Dinges et al., 2010;
Kunwar et al., 2013; Liu et al., 2009; Mothe et al., 2011). Although the
role of epitope conservation in the effect of MHC on HIV control
among progressors is not yet clear, it appears less likely that it differen-
tiates progressors from LTNP/EC bearing protective alleles. In larger
groups of B*57pos patients that include true LTNP/EC, the prevalence of
epitope sequence variations was comparable between LTNP/EC and
progressors (Bailey et al., 2006; Migueles et al., 2003; Miura et al.,
2009). In both groups, the CD8+ T-cell response targets epitopes
restricted by these protective class I proteins (Altfeld et al., 2003;
47S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58Goulder et al., 1996; Migueles et al., 2000). Nonetheless, most
HIV-infected individuals bearing protective alleles experience progres-
sive infection. This suggests that protective genotypes and preferential
epitope targeting are clearly not sufﬁcient for high-level HIV control
and do not distinguish LTNP/EC from progressors bearing protective
alleles (Bailey et al., 2006; Migueles et al., 2000, 2003; Miura et al.,
2009).
In contrast, there is a growing consensus that durable control among
patients bearing protective alleles is associated with superior CD8+
T-cell function (reviewed in Hersperger et al., 2011). Among the CD8+
T-cell functions that have most consistently distinguished LTNP/EC
from progressors are increased polyfunctionality, proliferation, loading
of cytotoxic proteins, virus suppressive ability and cytotoxic capacity
(Betts et al., 2006; Ferre et al., 2009; Hersperger et al., 2010; Migueles
et al., 2002, 2008; Saez-Cirion et al., 2007; Zimmerli et al., 2005).
Similarly, there is some evidence of better CD8+ T-cell functionality in
LTNP/EC macaques compared to progressors (Mendoza et al., 2013).
A better understanding of the contributions of epitope targeting and
conservation could potentially be obtained by investigating features of
the response shared between LTNP/EC with and without protective
alleles. Depending upon the case deﬁnition used, 59–79% of LTNP/EC
bear HLA B*27 or B*57 (Migueles and Connors, 2010). Thus far, the
CD8+ T-cell response of the remaining individuals has been anecdotally
reported and not well characterized (Hersperger et al., 2010; Lecuroux
et al., 2014; Migueles et al., 2002, 2008, 2009; Saez-Cirion et al., 2007,
2009). In the present study, we analyzed the epitope speciﬁcity in a
cohort of B*27/57neg LTNP/EC to provide greater insight into the
mechanisms of control over HIV replication. The responses in B*27/
57neg LTNP/EC recognized epitopes restricted by a variety of HLA class
I proteins similar to those of B*27/57neg progressors. These epitopes
were not distinguished by their conservation, but rather, varied to the
same degree as those restricted by other alleles. CD8+ T-cell mediated
killing of autologous HIV-infected targets was the parameter shared
between LTNP/EC with and without the B*27 or B*57 protective alleles.
This cytotoxicity was mediated through HLA proteins that are highly
prevalent, raising the possibility that vaccines or immunotherapies
that might induce cytotoxic function could do so in a large portion of
the population.
2. Experimental Procedures
2.1. Subjects
The NIAID Institutional Review Board approved this study. All
subjects were adults who provided written informed consent following
detailed protocol review with the Principal Investigator. PBMC were
collected by leukapheresis. HIV infection was determined by HIV-1/2
immunoassay (Abbott Laboratories, Abbott Park, IL) and Cambridge
Biotech HIV-1 Western blot (Maxim Biomedical, Inc., Rockville, MD).
All subjects acquired HIV infection in the USA and, therefore, are likely
infected with clade B viruses. LTNP/EC, including those not carrying
the classically protective HLA class I alleles B*27 and B*57 (n = 23)
and a randomly selected group of B*27/57pos LTNP/EC (n = 23),
were clinically healthy and had stable CD4+ T-cell counts, HIV-1 RNA
levels b50 copies/mL, no ART and no history of opportunistic diseases.
Slow (n = 6) and chronic (n = 7) progressors had detectable HIV-1
RNA levels (N1000–b10,000 or N10,000 copies/mL, respectively) and
declining CD4+ T-cell counts without ART, as previously deﬁned
(Migueles et al., 2008). HLA class I/II typing was performed by
sequence-speciﬁc hybridization (Migueles et al., 2000).
2.2. Optimal Epitope Determination of Immunodominant HIV-speciﬁc
CD8+ T-cells
Intracellular cytokine detection assays using cryopreserved periph-
eral blood mononuclear cells (PBMC) stimulated for 6 h with syntheticpeptides homologous with consensus clade B, HIV-1 sequences (ﬁnal
concentration, 2 μg/mL; NIH AIDS Research and Reference Reagent
Program, Germantown, MD) were performed as previously described
(Migueles et al., 2009). Responses above background were further
mapped with smaller peptide pools and individual 15-mer peptides.
In determining response breadth, recognition of two or more adjacent
15-mer peptides was addressed according to a previously published
algorithm (Frahm et al., 2004).
Determination of optimal epitopes was performedwith synthesized
truncations of the targeted 15-mer by sequential amino acid elimination
from either the N- or C-terminus resulting in 8–14 amino-acid long
peptides (Peptide 2.0, Inc., Chantilly, VA) (Hansen et al., 2013). HLA
restriction was conﬁrmed with peptide-pulsed, heterologous target
PBMC matched at a single HLA allele. Immunodominant responses
were the highest frequency responses (when rank ordered fromhighest
to lowest) that comprised at least 50% of the total magnitude in a single
patient orwere detected amongmultiple individualswith the sameHLA
type. All others were considered non-immunodominant. A response
was considered new if the epitope had not been previously reported
or if the restricting HLA differed from prior reports. “Predicted”
responses were included if at least two of the following three criteria
weremet: (1) a known epitopewithin the recognized protein sequence
and a restricting HLA matching one from the submitted haplotype
were located within the HIV immunology database by the LANL
Epitope Location Finder (ELF; www.hiv.lanl.gov/content/sequence/
ELF/epitope_analyzer.html); (2) a potential epitope possessed one or
more anchor residue motifs associated with the submitted HLA alleles
as determined by Motif Scan (www.hiv.lanl.gov/content/immunology/
motif_scan/motif_scan); or (3) a potential epitope within the recog-
nized peptide sequencewas predicted by the Immune EpitopeDatabase
(IEDB; tools.immuneepitope.org/mhci) or Propred-I (www.imtech.res.
in/raghava/propred1) algorithms to bind strongly with one of the
submitted HLA proteins at conservative 2% thresholds.
2.3. Shannon Entropy Score
Shannon entropy of HIV-1 peptides, used as a measure of variability
at the population level (Frahm et al., 2004), was derived by averaging
the entropy scores of the 8–15 amino acids comprising a particular
peptide, which had been averaged for each amino acid residue from
clade B protein alignments in the LANL database. Entropy scores were
determined for best-deﬁned (“A list”) CTL/CD8+ epitopes reported
in LANL (www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_
summary), epitopes known to be restricted by B27/57 from LANL and
epitopes targeted by the immunodominant responses of the B*27/
57neg patients in this study. These were compared with the entropy of
the major HIV-1 gene products by randomly selecting 1000 sequences
each from Nef, Gag and Pol sequences of lengths 8, 9, 10 and 11 amino
acids in proportion to the epitope lengths of the 3 combined epitope
groups (i.e., 13%, 8-mers; 60%, 9-mers; 17%, 10-mers; and 10%,
11-mers). Entropy scores were also determined for Gag overlapping
15-mer peptides and correlated with the prevalence of individuals
recognizing a given 15-mer.
2.4. HIV-speciﬁc CD8+ T-cell Cytotoxic Capacity
Cytotoxicity of autologous HIVSF162-infected CD4+ T-cell targets by
CD8+ T-cells that had been stimulated for 6 days was assessed by GrB
target cell activity and ICE, as described previously (Migueles et al.,
2008, 2009). To assess per-cell cytotoxic capacity, responses were
plotted against the true E/T ratios for each patient and the generated
group curves were compared, as described previously (Migueles et al.,
2008, 2009). Cells were combined at a plated E/T of 25:1. True E/T
ratios were derived from parallel measurements of the frequencies
of HIV-speciﬁc CD8+ T cells based on IFN-γ production (true effector
cell numbers) and the percentages of HIV p24+ T-cell targets (true
48 S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58target cell numbers). To conﬁrm the epitope speciﬁcities of the
immunodominant cytotoxic responses, GrB activity was measured after
co-incubating day 6 effectors for 1 h with autologous, un-infected CD4+
T-cell targets pulsed with either the immunodominant epitopes found
in the intracellular cytokine assays or an irrelevant peptide. To conﬁrm
the contribution of HLA class I restriction to the total cytotoxic responses,
GrB activity and ICE were measured after co-incubating day 6 effectors
with fresh heterologous un-infected orHIVSF162-infected targetsmatched
at a single HLA class I allele. Immunodominant responses were among
the highest responses and contributed ≥50% to the magnitude of the
total cytotoxic response in a single patient. To examine per-cell cytotoxic
capacity of immunodominant and non-immunodominant responses,
these were subsequently plotted against the true E/T ratios of each re-
sponse based on net true effector cell numbers (following co-incubation
of a given patient's effectors with heterologous HIVSF162-infected CD4+
T-cell targetsmatched at a single HLA locusminus background responses
to heterologous un-infected targets) and the true numbers of heterolo-
gous HIV p24+ T-cell targets.2.5. Flow Cytometry
Multiparameter ﬂow cytometry was performed according to
standard protocols. All staining was performed at 4 °C for 30 min with
the following antibodies (BD Biosciences): FITC-conjugated anti-CD3;
PerCP-conjugated anti-CD3 and anti-CD8; Am Cyan-conjugated
anti-CD8; APC-conjugated anti-CD4 and anti-IFN-γ; PE-conjugated
anti-CD8 and anti-CD69. RD1-conjugated anti-HIVp24 (Kc57; Beckman
Coulter, Inc., Brea, CA) was used to conﬁrm target cell infection and
measure elimination of p24-expressing cells. Samples were analyzed
on a FACSAria multi-laser cytometer (BD Biosciences) with FACSDiva0
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Fig. 1.HIV-speciﬁc CD8+ T-cell responses of B*27/57neg LTNP/EC are similar to those of B*27/57p
spanningHIV-1 (A) Nef, (B) Gag, (C) Pol and (D) total (sumof A–C) are shown for B*27/57neg LTN
Upon furthermapping, (E) the sum of the frequencies of IFN-γ+CD69+CD8+ T-cells and (F) the
viremic progressors. Horizontal lines represent median values. Comparisons were made usingsoftware. Data were analyzed using FlowJo software (TreeStar, San
Carlos, CA).
2.6. Statistical Analysis
Analysis of covariance was used to quantify the differences in GrB
activity and ICE among the various patient groups and among
immunodominant versus non-immunodominant responses over the
shared range of logged E/T ratios. Comparisons of independent groups
were made by the Wilcoxon two-sample test. Correlations were
determined by the Spearman rank method. The Bonferroni method
was used to adjust p values for multiple testing.
3. Results
3.1. HLA B*27/57neg LTNP/EC Have Clinical Features Similar to Those of
B*27/57pos LTNP/EC
LTNP/EC not bearing the classically protective HLA class I alleles B*27
or B*57 comprised 21% (23/112) of our entire LTNP/EC cohort (Migueles
and Connors, 2010) and had similar features to those of 23 randomly
selected B*27/57pos LTNP/EC (Table S1). B*27/57neg and B*27/57pos
LTNP/EC had similar, profound control over HIV (medianHIV RNA levels
b50 copies/mL in both groups; p N 0.5) for similarly long durations of
infection (medians, 17 versus 24 years, respectively; p N 0.5) and had
comparable CD4+ T-cell counts (medians, 913 versus 753 cells/mm3,
respectively; p N 0.5). In a group of 13 B*27/57neg viremic progressors
used as controls, viral RNA levels were signiﬁcantly higher (median,
10,443 copies/mL, p b 0.001 for all comparisons) and CD4+ T-cell counts
were signiﬁcantly lower (median, 461; p ≤ 0.001 for all comparisons;
Table S1) compared to LTNP/EC. Despite small sample sizes, theNe
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P/EC (n=23), B*27/57pos LTNP/EC (n=23) and B*27/57neg viremic progressors (n=13).
sum of the numbers of targeted peptides are shown for B*27/57neg LTNP/EC and B*27/57neg
the Wilcoxon two-sample test. Only signiﬁcant p values are shown.
Table 1
Dominant CD8+ T-cell responses in HLA B*27/57neg patients.
Patients Epitope Protein Frequency HLA Class I Epitope/HLA Patients Epitope Protein Frequency HLA Class I Epitope/HLA
LTNP/EC-1 EEMNLPGRW Pol 0.39 B44 Predicted/predicted SP-1 KEKGGLEGL Nef 2.04 B40 Predicted/predicted
HTDNGSNFTa Pol 0.77 C5 Conﬁrmed/conﬁrmed HTQGYFPDW Nef 1.82 B58 Conﬁrmed/conﬁrmed
LTNP/EC-2 GSNFTSTTVKAACWW Pol 0.52 GYFPDWQNYa Nef 2.17 B58 Conﬁrmed/conﬁrmed
LTNP/EC-3 SLYNTVATL Gag 0.2 A2 Conﬁrmed/predicted GKKKYKLKHIVWASR Gag 2.00
LTNP/EC-4 QVPLRPMTYK Nef 0.66 A3 Predicted/predicted LETSEGCRQIa Gag 3.33 B40 Conﬁrmed/conﬁrmed
LTFGWCFKLVPVEPE Nef 0.69 ILGQLQPSL Gag 2.20 A2 Predicted/predicted
MARELHPEY Nef 0.59 B35 Predicted/predicted ISPRTLNAW Gag 2.24 B58 Predicted/predicted
RLRPGGKKK Gag 1.67 A3 Conﬁrmed/predicted GVGGPGHKARV Gag 2.36 A2 Conﬁrmed/predicted
NANPDCKTI Gag 1.18 B51 Conﬁrmed/conﬁrmed TERQANFL Gag 1.61 B40 Conﬁrmed/predicted
GVGGPGHK Gag 0.6 A11 Predicted/predicted SP-2 TPQDLNTML Gag 3.99 C8 Conﬁrmed/conﬁrmed
LPPVVAKEI Pol 0.72 B51 Conﬁrmed/conﬁrmed SPTRRELQVWGRDNN Pol 1.37
LTNP/EC-5 TPQDLNTML Gag 0.69 B42 Conﬁrmed/conﬁrmed VTDSQYALa Pol 1.23 C8 Conﬁrmed/conﬁrmed
LTNP/EC-6 VNDIQKLVGKLNWAS Pol 0.3 SP-3 KEKGGLEGL Nef 1 B40 Predicted/predicted
TAYFLLKLAGR Pol 0.25 A33 Predicted/predicted GELDRWEKI Gag 0.5 B40 Predicted/predicted
STTVKAACWW Pol 0.4 B58 Predicted/predicted RPLVTIKI Pol 0.46 B51 Conﬁrmed/conﬁrmed
LTNP/EC-7 RRAEPAADGVGAVSR Nef 1.18 QWPLTEEKI Pol 0.79 B51 Predicted/predicted
AAVDLSHFLa Nef 0.7 B58 Conﬁrmed/conﬁrmed SAGERIVDI Pol 0.91 B51 Predicted/predicted
VTDSQYALa Pol 1 C8 Conﬁrmed/conﬁrmed SP-4 GYFPDWQNYa Nef 0.84 C2 Conﬁrmed/conﬁrmed
KQITKIQNF Pol 0.77 B58 Predicted/predicted LTFGWCFKLVPVEPE Nef 0.9
LTNP/EC-8 IRYQYNVLPa Pol 0.69 B73 Conﬁrmed/conﬁrmed RAEQASQEV Gag 2.56 B51 Predicted/predicted
SPAIFQSSM Pol 0.5 B35/C4 Predicted/predicted NANPDCKTI Gag 1.65 B51 Conﬁrmed/conﬁrmed
HTDNGSNFTSTTVKA Pol 0.46 VLAEAMSQV Gag 2.37 A2 Predicted/predicted
GIKQEFGIPYNPQSQ Pol 0.46 RPLVTIKI Pol 0.8 B51 Conﬁrmed/conﬁrmed
VVESMNKEL Pol 0.55 B35 Predicted/predicted HTDNGSNFTa Pol 2.76 C5 Conﬁrmed/conﬁrmed
RDQAEHLKTAVQMAV Pol 0.53 IHNFKRKGGIGGYSA Pol 1.66
TDIQTKELQKQITKI Pol 0.57 SP-5 QVPLRPMTYK Nef 1.24 A3 Predicted/predicted
KIQNFRVYY Pol 0.5 A32 Predicted/predicted ETFYVDGAANRETKL Pol 0.64
LTNP/EC-10 AAVDLSHFL Nef 0.55 C3 Conﬁrmed/conﬁrmed KLAGRWPVK Pol 0.6 A3 Predicted/predicted
PIVQNLQGQMVHQAI Gag 0.37 SP-6 SLYNTVATL Gag 1.33 A2 Conﬁrmed/predicted
LTNP/EC-11 AAVDLSHFLa Nef 0.51 B14 Conﬁrmed/conﬁrmed SEGATPQDL Gag 1.92 B44 Conﬁrmed/conﬁrmed
DRFYKTLRA Gag 1.14 B14 Conﬁrmed/conﬁrmed EIYKRWII Gag 1.50 B8 Conﬁrmed/predicted
FKRKGGIGGY Pol 2.2 B15 Conﬁrmed/predicted CP-1 SRLAFHHMAa Nef 0.74 B8 Conﬁrmed/conﬁrmed
(continued on next page)
49
S.A
.M
igueles
etal./EBioM
edicine
2
(2015)
46
–58
Table 1 (continued)
Patients Epitope Protein Frequency HLA Class I Epitope/HLA Patients Epitope Protein Frequency HLA Class I Epitope/HLA
LTNP/EC-12 WLEAQEEEEVGFPVR Nef 0.27 HQRIEVKDTKEALEK Gag 1.32
RQDILDLW Nef 0.66 B13 Predicted/predicted EIYKRWII Gag 1.59 B8 Conﬁrmed/predicted
LTNP/EC-13 LTFGWCFKL Nef 1.03 B15 Conﬁrmed/predicted NANPDCKTI Gag 3.10 B51 Conﬁrmed/conﬁrmed
LYNTVATLY Gag 4.17 B44 Conﬁrmed/predicted RQANFLGK Gag 1.38 A11 Predicted/predicted
LTNP/EC-14 AVSRDLEK Nef 2.09 A11 Predicted/predicted RPLVTIKI Pol 1.43 B51 Conﬁrmed/conﬁrmed
LTNP/EC-15 DRWEKIRLRPGa Gag 1.45 B40 Conﬁrmed/conﬁrmed LPPVVAKEI Pol 1.45 B51 Conﬁrmed/conﬁrmed
MTNNPPIPV Gag 1.60 C6 Predicted/predicted CP-2 FPDWQNYTPG Nef 1.56 B51 Predicted/predicted
LTNP/EC-16 SRLAFHHMAa Nef 1.76 B8 Conﬁrmed/conﬁrmed EVIPMFSAL Gag 0.84 B7 Predicted/predicted
YSPTSILDI Gag 1.61 C1 Conﬁrmed/conﬁrmed LPPVVAKEI Pol 0.7 B51 Conﬁrmed/conﬁrmed
LTNP/EC-17 YPLTFGWCF Nef 1.21 B35 Conﬁrmed/conﬁrmed CP-3 RPLVTIKI Pol 1.59 B51 Conﬁrmed/conﬁrmed
NANPDCKTI Gag 1.52 B35 Conﬁrmed/predicted CP-4 YPLTFGWCF Nef 1.22 B51/C14 Predicted/predicted
YRDSRDPLWa Pol 3.24 B38 Conﬁrmed/conﬁrmed RAEQASQEV Gag 4.29 B51 Predicted/predicted
LTNP/EC-18 MVHQAISPR Gag 0.35 A68 Predicted/predicted NANPDCKTI Gag 2.00 B51 Conﬁrmed/conﬁrmed
TERQANFL Gag 0.51 B40 Conﬁrmed/predicted HTDNGSNFTa Pol 1.17 C5 Conﬁrmed/conﬁrmed
LTNP/EC-19 TPQDLNTML Gag 1.23 B81 Conﬁrmed/conﬁrmed CP-5 RERMRRAEPAADGVG Nef 0.73
LTNP/EC-20 FLKEKGGL Nef 0.7 B8 Conﬁrmed/predicted SEGATPQDL Gag 2.30 B44 Conﬁrmed/conﬁrmed
LTNP/EC-21 TPQDLNTML Gag 1.5 B81 Conﬁrmed/conﬁrmed CP-6 RPQVPLRPM Nef 1.13 C4 Predicted/predicted
VTDSQYALa Pol 0.55 C8 Conﬁrmed/conﬁrmed GLNKIVRMY Gag 3.64 B15 Predicted/predicted
FKRKGGIGGY Pol 0.75 B15 Conﬁrmed/conﬁrmed FIKVRQYDQILIEIC Pol 0.78
LTNP/EC-22 TPQDLNTML Gag 0.3 B42 Conﬁrmed/conﬁrmed TQIGCTLNF Pol 0.72 B15 Predicted/predicted
LTNP/EC-23 FLKEKGGL Nef 1.1 B8 Conﬁrmed/predicted KQITKIQNF Pol 0.81 B15 Predicted/predicted
DRFYKTLRA Gag 0.57 B14 Conﬁrmed/conﬁrmed CP-7 FLKEKGGL Nef 1.28 A2 Predicted/predicted
NETPGIRYQY Pol 0.86 B18 Predicted/predicted
FYVDGAANR Pol 1.18 A33 Predicted/predicted
a Epitope-speciﬁc responses not previously reported.
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51S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58composition of the two LTNP/EC sub-groups also appeared to be similar
with respect to gender (p N 0.5), race/ethnicity (p N 0.5) and mode of
HIV acquisition (p N 0.5).
Fifteen out of 23 (65%) of the B*27/57neg LTNP/EC carried at least one
weakly protective HLA allele previously demonstrated to be enriched in
LTNP/EC, including B*13, 15, 44, 51, 58 and 81 (Flores-Villanueva et al.,
2001; Frahm et al., 2006; Goulder et al., 2000; Honeyborne et al.,
2007; Kaslow et al., 1996; Zhang et al., 2011). However, no particular
HLA type predominated among these 23 B*27/57neg LTNP/EC. In
addition, 8/23 B*27/57neg LTNP/EC had HLA alleles considered to be
neutral or deleterious regarding their impact on disease progression.
3.2. Immunodominant CD8+ T-cell Responses of B*27/57neg LTNP/EC Are
Restricted by Various HLA Proteins
To understand the contribution of epitope targeting to immunologic
control in B*27/57neg LTNP/EC, individual speciﬁcities weremapped and
the HLA molecule they bound was determined. Pools of synthetic
15-mer peptides, overlapping by 10 amino acids (see Experimental
Procedures) and spanning the major HIV-1 gene products Nef, Gag
and Pol were used in intracellular cytokine assays (Fig. 1). The magni-
tude of the gene product-speciﬁc CD8+ T-cell responses was variable
and tended to be highest for Gag, as observed in prior studies (Betts
et al., 2001; Migueles et al., 2000, 2002; Saez-Cirion et al., 2007).
Although the responses tended to be higher for 13 viremic progressors
(untreated slow progressors and typical progressors combined), the
gene product-speciﬁc and total HIV-speciﬁc CD8+ T-cell responses were
not signiﬁcantly different between 23 B*27/57neg and 23 B*27/57pos
LTNP/EC (p N 0.05 for all comparisons; Fig. 1A–D).
Using smaller pools and individual peptides, virus-speciﬁc CD8+
T-cell responses were further mapped down to the individual 15-mersTable 2
Conﬁrmed (by epitope) dominant CD8+ T-cell responses by HLA restriction element.
HLA class I protein Epitope HIV-1 protein Recognition frequencya
A2 SLYNTVATL Gag 5/14
A2 GVGGPGHKARV Gag 2/14
A3 RLRPGGKKK Gag 1/5
B8 FLKEKGGL Nef 3/5
B8 SRLAFHHMAc Nef 2/5
B8 EIYKRWII Gag 4/5
B14 DRFYKTLRA Gag 3/3
B15 LTFGWCFKL Nef 2/8
B15 FKRKGGIGGY Pol 4/8
B35 YPLTFGWCF Nef 2/4
B38 YRDSRDPLWc Pol 1/1
B40 DRWEKIRLRPGc Gag 3/4
B40 LETSEGCRQIc Gag 1/4
B40 TERQANFL Gag 3/4
B44 LYNTVATLY Gag 2/10
B44 SEGATPQDL Gag 2/10
B51 RPLVTIKI Pol 4/8
B51 LPPVVAKEI Pol 7/8
B58 HTQGYFPDW Nef 1/4
B73 IRYQYNVLPc Pol 1/1
C1 YSPTSILDI Gag 1/1
C5 HTDNGSNFTc Pol 3/5
C8 VTDSQYALc Pol 3/5
B14 AAVDLSHFLc Nef 1/3
B58 AAVDLSHFLc Nef 1/4
C3 AAVDLSHFL Nef 3/7
B58 GYFPDWQNYc Nef 1/4
C2 GYFPDWQNYc Nef 2/7
B42 TPQDLNTML Gag 2/2
B81 TPQDLNTML Gag 2/2
C8 TPQDLNTML Gag 2/5
B35 NANPDCKTI Gag 2/4
B51 NANPDCKTI Gag 4/8
a Number of individuals recognizing the 15-mer peptide and/or optimal epitope out of thos
b Number of individuals with a dominant response to the peptide out of those recognizing t
c Epitope-speciﬁc responses not previously reported.(Tables S2–4 and Fig. 1E, F). In this analysis, the frequencies of the
total responses targeting 15-mer peptides were signiﬁcantly lower in
22 B*27/57neg LTNP/EC than 13 B*27/57neg progressors (2.0% versus
9.7%, p b 0.001; Fig. 1E), consistent with the responses measured to
the peptide pools (Fig. 1A–D). Moreover, fewer individual 15-mer pep-
tides were targeted by the CD8+ T-cell responses of B*27/57neg LTNP/EC
than B*27/57neg progressors (median 5 versus 15, p b 0.001; Tables S2–4
and Fig. 1F). In summary, the HIV-speciﬁc CD8+ T-cell responses of
B*27/57neg LTNP/EC were readily detectable, variable in magnitude and
narrow in breadth (Migueles et al., 2000, 2002).
To further resolve the speciﬁcities of the immunodominant
HIV-speciﬁc CD8+ T-cell responses of B*27/57neg patients, responses
targeting individual 15-mer peptides were ﬁne mapped if their
frequency was ≥0.2% and if they were either among the highest of a
given patient or were recognized by multiple patients. Fine mapping
was performed with synthesized truncations, 8–14 amino acids long,
of the recognized 15-mer peptides in intracellular cytokine assays.
Once the optimal epitopes were determined, HLA class I restriction
was conﬁrmed in the same assays with peptide-pulsed, heterologous
targets matched at a single HLA locus. When possible, optimal epitopes
and/or HLA restriction elements were predicted for unmapped
dominant responses (see Experimental Procedures). Epitope-speciﬁc
CD8+ T-cells ranged in frequency from 0.2 to 4.3% (Tables 1, 2).
Remarkably, many B*27/57neg patients targeted speciﬁcities not
previously described. Eleven conﬁrmed responses were new: 5 in Nef
(B8-SA9, B14-AL9, B58-AL9, B58-GY9 and C2-GY9), 2 in Gag (B40-
DG11 and B40-LI10) and 4 in Pol (B38-YW9, B73-IP9, C5-HT9 and
C8-VL8; Tables 1–2). These were immunodominant in 14 B*27/57neg
patients: 8 LTNP/EC, 4 slow progressors and 2 chronic progressors
(Table 2). Among B*27/57neg LTNP/EC, some responses were restricted
by class I proteins that have been enriched, albeit less so than B27 andDominant response frequencyb Patients with dominant response HLA
2/5 LTNP/EC-3, SP-6 Predicted
1/2 SP-1 Predicted
1/1 LTNP/EC-4 Predicted
2/3 LTNP/EC-20, LTNP/EC-23 Predicted
1/2 LTNP/EC-16, CP-1 Conﬁrmed
2/4 SP-6, CP-1 Predicted
2/3 LTNP/EC-11, LTNP/EC-23 Conﬁrmed
1/2 LTNP/EC-13 Predicted
2/4 LTNP/EC-11, LTNP/EC-21 Conﬁrmed
1/2 LTNP/EC-17 Conﬁrmed
1/1 LTNP/EC-17 Conﬁrmed
1/3 LTNP/EC-15 Conﬁrmed
1/1 SP-1 Conﬁrmed
2/3 LTNP/EC-18, SP-1 Predicted
1/2 LTNP/EC-13 Predicted
2/2 SP-6, CP-5 Conﬁrmed
4/4 SP-3, SP-4, CP-1, CP-3 Conﬁrmed
3/7 LTNP/EC-4, CP-1, CP-2 Conﬁrmed
1/1 SP-1 Conﬁrmed
1/1 LTNP/EC-8 Conﬁrmed
1/1 LTNP/EC-16 Conﬁrmed
3/3 LTNP/EC-1, SP-4, CP-4 Conﬁrmed
3/3 LTNP/EC-7, LTNP/EC-21, SP-2 Conﬁrmed
1/1 LTNP/EC-11 Conﬁrmed
1/1 LTNP/EC-7 Conﬁrmed
1/3 LTNP/EC-10 Conﬁrmed
1/1 SP-1 Conﬁrmed
1/2 SP-4 Conﬁrmed
2/2 LTNP/EC-5, LTNP/EC-22 Conﬁrmed
2/2 LTNP/EC-19, LTNP/EC-21 Conﬁrmed
1/2 SP-2 Conﬁrmed
1/2 LTNP/EC-17 Predicted
3/4 LTNP/EC-4, SP-4, CP-1, CP-4 Conﬁrmed
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52 S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58B57, in LTNP/EC cohorts, such as, B15, B44, B51, B58 and B81
(Flores-Villanueva et al., 2001; Frahm et al., 2006; Goulder et al., 2000;
Kaslow et al., 1996; Zhang et al., 2011). However, these same responses
were also identiﬁed in progressors. B51-restricted responseswere partic-
ularly immunodominantwith frequent recognition of the LI9, RI8 andNI9
epitopes (Table 2) (Zhang et al., 2011). Interestingly, many responses in
LTNP/EC were restricted by historically neutral, deleterious or uncom-
monHLAproteins, such as B8, B35 andB73, respectively. The rare B*73 al-
lele was present in only 4 of the 2020 HLA typed, HIV-positive patients
screened to date in our outpatient clinic, yet B73 restricted the most
immunodominant response of LTNP/EC-8. In addition, HLA-C proteins
(e.g., C1, C3, C5 and C8) restricted some dominant responses. The
immunodominance of HLA-C1-restricted responses is consistent with
prior observations (Buranapraditkun et al., 2011) and might be due to
higher surface expression and better antigen presentation by particular
HLA-C proteins (Thomas et al., 2009).
Remarkably, some immunodominant epitopeswere cross-restricted
by different HLA proteins in different patients. For example, the highly
conserved TL9 epitope (Goulder et al., 2000; Liu et al., 2013) was
restricted by B42 in two LTNP/EC, B81 in two other LTNP/EC, and C8 in
a slow progressor (Table 2). In only 7/67 total conﬁrmed or predicted
immunodominant responseswere epitopes, known to also be restricted
by B27 or B57, targeted: 5 conﬁrmed responses in Nef (B14-AL9 of
LTNP/EC-11, B58-AL9 of LTNP/EC-7, C3-AL9 of LTNP/EC-10, B15-LL9 of
LTNP/EC-13 and B58-HW9 of SP-1); 1 predicted response in Gag
(B58-IW9 of SP-1); and 1 predicted response in Pol (B58-SW10 of
LTNP/EC-6; Tables 1, 2) (Frahm et al., 2005; Goulder et al., 1996). Of
immunodominant HIV-speciﬁc CD8+ T-cell responses of the B*27/57neg
patients in this study, more than 2/3 were not directed against the same
or overlapping sequences as those restricted by B27 or B57. Rather,
these were scattered over the HIV proteome and distal to known B27-
or B57-restricted responses. These data suggest that targeting areas
within or close to those typically targeted by B*27/57pos LTNP/EC is not a
requirement for immunologic control of HIV-1.
3.3. Immunodominant Responses of B*27/57neg LTNP/EC Target Peptides
Not Differentiated by Entropy
It has been suggested that the association between B*57 or B*27 al-
leles and lower viral loads is mediated by targeting functionally critical
and, therefore, more highly conserved parts of the proteome (Allen
et al., 2005; Brockman et al., 2007; Crawford et al., 2007; Friedrich
et al., 2004; Goulder et al., 1997; Leslie et al., 2004; Liu et al., 2013;
Peyerl et al., 2004). To examinewhether recognition prevalencewas re-
lated to the degree of peptide conservation, Shannon entropy was used
as a measure of HIV-1 peptide variability or diversity (see Experimental
Procedures). Lower entropy scores correspond to more conserved pep-
tides (Frahm et al., 2004). Entropy of Gag 15-mers was then plotted
with the number of B*27/57neg patients mounting any response above
background to each 15-mer peptide (Fig. 2A). Variable recognition of
Gag 15-merswas found in both B*27/57neg LTNP/EC and progressors. Al-
though entropy did not correlate with the total number of patients rec-
ognizing each 15-mer (p N 0.05), highly variable sequences were
targeted infrequently (Fig. 2A). These results suggest that the Gag-
speciﬁc CD8+ T-cells of both B*27/57neg LTNP/EC and progressors were
similarly scattered throughout Gag, but tended to spare regions of
high entropy (Frahm et al., 2004; Sunshine et al., 2014).
Since 15-mer peptides contain amino acids lying outside of putative
epitopes, calculated entropies of the former may not accurately reﬂect
the variability of actual targeted 9-11-mer epitopes. To circumvent
this issue, entropy scores were determined for the conﬁrmed and
predicted epitopes targeted by the immunodominant CD8+ T-cell
responses of the B*27/57neg patients in this study (Tables 1–2). Consid-
ering all Nef, Gag and Pol epitopes, median entropies did not differ
signiﬁcantly between LTNP/EC and progressors (p N 0.05 for all compar-
isons; Fig. 2B).
53S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58To determine whether the variability of epitopes restricted by non-
B27/57 proteins differed from that of B27- or B57-restricted epitopes,
the entropies of epitopes targeted by the immunodominant responses
in this study were compared with entropies of the following peptides:
best-deﬁned (“A list”) CTL/CD8+ epitopes in the LANL database, those
restricted by B27 and B57 in LANL, and pools of 1000 pseudo-epitopes
derived from each major gene product (see Experimental Procedures).
By this method, the median entropy of total Gag (1000 Gag, 0.25) or
Pol (1000 Pol, 0.16) was not signiﬁcantly different from the epitopes
targeted in these gene products (p N 0.05 and p ≥ 0.5 for all compari-
sons, respectively; Fig. 2C). The median entropy of the more highly
variable Nef (1000 Nef, 0.40) was signiﬁcantly higher than the median
entropies of the best-deﬁned Nef epitopes from LANL (0.24; p =
0.004) and Nef epitopes identiﬁed in the current study (0.18; p =
0.005) and tended to be higher than known B27/57-restricted Nef
epitopes (0.28; p = 0.09). However, the entropies of the Nef
epitope groups were comparable to each other (p N 0.5 for all compari-
sons; Fig. 2C). Thus, the variability of epitopes targeted by the
immunodominant virus-speciﬁc CD8+ T-cell responses of B*27/57neg
patients were similar between LTNP/EC and progressors, and no more
conserved than epitopes restricted by HLAs previously associated or
not associated with immunologic control of HIV-1. These ﬁndings
suggest that the conservation of targeted epitopes is not a parameter
that uniquely identiﬁes patients with immunologic control of HIV-1.
3.4. Gag Epitopes of Autologous Viruses Contained Few Variations in
B*27/57neg LTNP/EC and Progressors
Immunodominant HIV-speciﬁc CD8+ T-cell responses of both
B*27/57neg LTNP/EC and progressors targeted relatively conserved
regions of HIV-1 based on entropy measurements. Even though muta-
tions conferring immune escape or impaired replication capacity have
not consistently distinguished B*27/57pos LTNP/EC from progressors
(Bailey et al., 2006; Blankson et al., 2007; Buckheit et al., 2012; Lamine
et al., 2007; Migueles et al., 2003; Miura et al., 2009; Navis et al.,
2007), it remained possible that differences in sequence variations
between B*27/57neg LTNP/EC and progressors might account for differ-
ential control. Therefore, the autologous gag gene was sequenced in
10 B*27/57neg subjects (5 LTNP/EC, 5 progressors). Most regions
recognized by the immunodominant responses of these individuals
contained few variations and were homologous with the HIV-1 clade
B consensus sequence (Table 3). A notable exception was the K9R
variant of the LTNP/EC-4's A3-RK9 epitope that has inconsistently
been associated with loss of recognition (Bansal et al., 2005; Horton
et al., 2006). Infrequent variations involving TCR contact residues
were observed, but these do not necessarily confer escape (Bailey
et al., 2006; Migueles et al., 2003; Pohlmeyer et al., 2013). No putative
upstream or downstream compensatory mutations were found (data
not shown). Altogether, these ﬁndings suggest sequence variations
that might confer escape or reduced replicative capacity do occur in
some individuals, but sequence variations do not clearly differentiate
most HLA-matched LTNP/EC from progressors (Bailey et al., 2006;
Blankson et al., 2007; Buckheit et al., 2012; Lamine et al., 2007;
Migueles et al., 2003; Miura et al., 2009; Navis et al., 2007).
3.5. HIV-speciﬁc CD8+ T-cells of B*27/57neg LTNP/EC Mediate Potent
Cytotoxicity
Qualitative features of virus-speciﬁc CD8+T-cells, such as proliferative
and cytotoxic capacities,measured after several days of re-stimulation are
far and away themost robust parameters differentiating the responses of
B*27/57pos LTNP/EC from progressors (reviewed in Hersperger et al.,
2011). HIV-speciﬁc CD8+ T-cell cytotoxic responses of 17 B*27/57neg
LTNP/EC, measured by the median percent of GrB+ targets (34%) or
infected CD4+T-cell elimination (ICE; 74.3%),were high overall and com-
parable to those of 18 B*27/57pos LTNP/EC (33.2%, p N 0.5 and 82.6%,p N 0.05, respectively). These cytotoxic responses were signiﬁcantly
higher than those of 18 progressors, including 5 who were B*27/57pos
(15.3%, p b 0.001 and 41.4%, p b 0.001, respectively; Fig. 3A, B).
Given the greater proliferative capacity of HIV-speciﬁc CD8+ T-cells
of LTNP/EC compared to progressors, it is critical to additionally
measure cytotoxic capacity on a per-cell basis. When the cytotoxic
responses of each patient groupwere plotted against the truemeasured
effector-to-target (E/T) ratios and compared, the cytotoxicity curves of
B*27/57neg and B*27/57pos LTNP/EC were superimposable with each
other (p N 0.5) and differed signiﬁcantly over the shared range of E/T
from that of progressors (p b 0.001 for all comparisons; Fig. 3C, D).
These ﬁndings support that the re-stimulated HIV-speciﬁc CD8+
T-cells of B*27/57neg LTNP/EC exhibit both increased bulk and per-cell
cytotoxicity compared to progressors.
We next sought to determine the peptide speciﬁcities and HLA
restricting elements responsible for CD8+ T-cell-mediated killing of
autologous HIV-infected CD4+ T-cell targets in B*27/57neg LTNP/EC.
First, CD8+ T-cell effectors were co-incubated for 1 h with autologous
uninfected CD4+ T-cell targets pulsed with either irrelevant peptides
or epitopes that had induced the highest responses in the intracellular
cytokine assays for a particular patient (Table 1). In most instances,
greatest cytotoxicity was observed against targets pulsed with
peptides recognized by immunodominant responses in intracellular
cytokine assays (representative LTNP/EC 19, Fig. 4A). To determine
the relative contribution of each HLA restriction element to the
total cytotoxic response, expanded HIV-speciﬁc CD8+ T-cells were
co-incubated with heterologous uninfected and HIV-infected CD4+
T-cell targets matched at a single locus (Fig. 4B). In 6 of 7 cases
(excluding one representative B*57pos LTNP/EC), the HLA class
I-restricted CD8+ T-cell responses that were immunodominant in
the intracellular cytokine assays contributed most signiﬁcantly to
the total cytotoxic response for each individual (Tables 1, 2 and
Fig. 4B). Of note, three alleles previously associated with lower viral
loads, B*51, B*58 and B*81, were reproducibly immunodominant.
These results suggested that the HLA class I-restricted CD8+ T-cell
responses determined to be immunodominant in the intracellular
cytokine assays were typically the same ones to preferentially expand
and mediate most cytotoxicity (Horton et al., 2006; Migueles et al.,
2000, 2002, 2008).
It remained possible that greater killing through a given HLA
molecule for a given patient might simply be due to a higher response
frequency. To further understand the relative contribution of
cytotoxic capacity and frequency, the 10 immunodominant and 11
non-immunodominant cytotoxic responses from the 7 aforementioned
B*27/57neg LTNP/EC were plotted against the measured E/T ratios and
compared. The per-cell cytotoxic capacity of immunodominant re-
sponses was signiﬁcantly greater than that of non-immunodominant
responses measured by either GrB activity (p = 0.03; Fig. 4C) or ICE
(p = 0.02; Fig. 4D). These results suggest that B*27/57neg LTNP/EC
share with B*27/57pos LTNP/EC the ability to mediate highly potent
cytotoxicity against autologous HIV-infected CD4+ T-cells. Further,
such responses can be mediated through HLAs not previously associated
with protection that are highly prevalent in the human population.
4. Discussion
The results of the present study provide several important insights
regarding the roles of CD8+ T-cell function and speciﬁcity in immuno-
logic control of HIV-1 infection. Over the past several years it has been
suggested that protective alleles, such as B*27 and B*57, mediate their
effect through speciﬁcity (Allen et al., 2005; Brockman et al., 2007;
Crawford et al., 2007; Friedrich et al., 2004; Goulder et al., 1997; Leslie
et al., 2004; Pereyra et al., 2014; Peyerl et al., 2004), which might
occur by targeting structurally or functionally critical areas of the
proteome. Escapemutations, if they occur,would result in a large ﬁtness
cost, constraining viral replication. However, the results of the present
54 S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58study are not consistent with this hypothesis. Many B*27/57neg patients
studied here had no alleles even weakly associated with reduced viral
load, indicating that a protective HLA background is not required for
high-level immune control. Many B*27/57neg LTNP/EC targeted areas of
the proteome non-overlapping with, and in most cases quite distal to,
areas containing B27/57-restricted peptides. Furthermore, the epitopes
they targeted were not distinguished from progressors by greater con-
servation scores or by a lack or excess of escape mutations. Response
features shared between B*27/57neg and B*27/57pos LTNP/ECwere killing
of autologous CD4+ T-cells by CD8+ T-cells with potent per-cell
cytotoxic capacity. These results suggest that the effect of protective
HLAs is not necessarily the result of presentation of particularly
constrained epitopes. Rather, effective cytotoxicity associated with
immunologic control may be mediated through a broad array of
epitopes and HLA molecules.
The results of the present study, to some extent, may narrow the
likely explanations for how protective HLAs mediate their effects.
They suggest that although favorable HLAs may tilt the balance toward
immunologic control of HIV, potent cytotoxicity can be mediated
through relatively common epitopes presented by HLAs not associated
with protection. HLA-peptide-T-cell receptor interactions might impact
the control of viral replication based upon peptide/HLA stoichiometry,
binding afﬁnity, or signal strength, among other factors. In the present
study, some B*27/57neg LTNP/EC did have alleles, such as B*15, B*44,Ne
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Fig. 2. Immunodominant responses of both B*27/57neg LTNP/EC and progressors target conserv
57neg progressors (n= 13, solid gray bars)with signiﬁcant IFN-γ+CD69+CD8+ T-cell responses
entropy scores for each 15-mer. Block arrows identify sequence positions corresponding to B2
white) and mapped Gag epitopes targeted by immunodominant CD8+ T-cell responses of B*2
conﬁrmed and predicted Nef (squares), Gag (triangles) and Pol (diamonds) epitopes targeted
progressors (solid gray symbols) are shown. (C) Entropy scores of 1000 pseudo-epitopes in N
57-restricted epitopes from LANL and epitopes recognized by B*27/57neg subjects (non-B27/57
the Wilcoxon two-sample test. Only signiﬁcant p values are shown as **(p b 0.01).B*51, B*58 and B*81, that have predisposed individuals to more
favorable outcomes (Flores-Villanueva et al., 2001; Frahm et al., 2006;
Goulder et al., 2000; Kaslow et al., 1996; Zhang et al., 2011). However,
no particular HLA type predominated and approximately 1/3 possessed
neutral, deleterious or rare HLA alleles. Taken together these data
suggest that the impact of HLA on the development of the LTNP/EC
phenotype is not based upon the peptides that are recognized. Although
bearing an HLA allele may favor development of the LTNP/EC
phenotype, the factors(s) that dictate which patients with a given allele
will ultimately restrict virus replication remain open questions. Never-
theless, our results indicate that these factors are highly related to
HIV-speciﬁc CD8+ T-cell cytotoxic capacity.
We did not observe that epitope conservation was a parameter
uniquely shared between LTNP/EC with and without protective alleles.
An association between lower HIV RNA levels and preferential recogni-
tion of conserved epitopes has been suggested in some acute and chron-
ic infection cohorts regardless of HLA type (Dinges et al., 2010; Kunwar
et al., 2013; Liu et al., 2009, 2013;Mothe et al., 2011). By contrast, in the
present study, the entropies of peptides recognized by the CD8+ T-cells
of B*27/57neg LTNP/EC and progressors were similar. Responses did tend
to exist outside highly variable stretches of the proteome, consistent
with some with prior reports (Frahm et al., 2004; Yusim et al., 2002).
However, epitopes targeted by B*27/57neg LTNP/EC had the same medi-
an entropy as that of epitopes targeted in B*27/57pos LTNP/EC, and the10
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55S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58same as that of over 125 well-characterized epitopes restricted by 39
HLA proteins in LANL, the vast majority of which are not associated
with reduced viral load. Our results contrast with a very recent study
that found an association between immunologic control and targeting
of particular epitopes thought to affect HIV protein stability (Pereyra
et al., 2014). However, the methods differ from the present study in
that these investigators used pre-deﬁned optimal epitopes, rather
than mapped responses, and an in silico analysis that did not directly
compare targeting among HLA-matched patients with or without con-
trol of HIV. In summary, our results suggest that although a highly var-
iable peptide likely cannot mediate control, large numbers of peptides
throughout the HIV proteome are sufﬁciently conserved to mediate
potent restriction of HIV replication.
We did ﬁnd, however, that B*57/27neg LTNP/EC uniformly shared
with B*57/27pos LTNP/EC the ability to mediate potent cytotoxicity. In
prior work, immunologic control in LTNP/EC was not associated with
the frequency of HIV-speciﬁc CD8+ T cells, surface phenotypic markers,
or avidity, among other factors (Hersperger et al., 2011; Migueles et al.,
2000, 2003, 2008, 2009). It was also only weakly associated with direct
cytotoxicity when using non-restimulated effectors, but was most
compellingly associatedwith CD8+ T-cell cytotoxic capacitywhenmea-
sured after 6 days of incubation with autologous HIV-infected targets
(Migueles et al., 2008, 2009). This result is potentially consistent with
some prior work suggesting that cytotoxic capacity might be shared
between LTNP/EC with and without protective alleles (Hersperger
et al., 2010; Lecuroux et al., 2014). The homogeneity in cytotoxic capac-
ity we observed among LTNP/ECmay be interpreted to differ with otherwork that has reported heterogeneity of CD8+ T-cell-mediated virus
suppression among LTNP/EC, including individuals lacking protective
HLA alleles (Lecuroux et al., 2014; Saez-Cirion et al., 2009). These
potentially discrepant resultsmay simply bedue to differences in exper-
imental conditions used in virus suppression assays compared to assays
of cytotoxic capacity. While it remains possible that alternative mecha-
nisms are responsible for controlling HIV in some LTNP/EC, these previ-
ous reports and the current study nonetheless suggest that most LTNP/
EC with or without protective HLA alleles possess HIV-speciﬁc CD8+ T-
cells with robust virus suppressive and cytotoxic capabilities.
It is important to note that in many cases we observed concordance
among protective HLA alleles, immunodominance of responses restrict-
ed by those alleles, expansion potential, and cytotoxic capacity. The
numerically immunodominant response was often restricted by an
HLA previously described as weakly associated with lower viral loads
such as B13, 15, 44, 51, 58 and 81. In B*27/57neg LTNP/EC, these same
responses efﬁciently expanded in vitro and mediated potent cytotoxic-
ity. This concordance is consistent with ﬁndings in B*27/57pos patients
during primary infection, non-progressive chronic infection or follow-
ing vaccination (Altfeld et al., 2003; Horton et al., 2006; Migueles
et al., 2000, 2002, 2008, 2009, 2011; Saez-Cirion et al., 2007, 2009).
However, regardless of HLA type, greater cytotoxicity in vitro was not
simply due to greater effector numbers, but also due to greater cytotoxic
capacity on a per-cell basis. Taken together, we observed that HLAs
associated with lower viral loads often restrict immunodominant
responses that preferentially expand, upregulate cytotoxic proteins
and efﬁciently lyse HIV-infected CD4+ T-cell targets.
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56 S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58Our study has some limitations. A potential shortcoming of our
epitope mapping approach was lack of inclusion of variant peptides. Al-
though our results are quite consistent with the comparable recognition
of a larger panel of conserved and frequently occurring variant epitopes
recently reported between LTNP/EC and progressors (Sunshine et al.,
2014), our methods could have potentially biased our results toward
detecting responses targeting conserved sequences. In addition, we did
not establish cause-and-effect relationships between increased virus-
speciﬁc CD8+ T-cell proliferative and cytotoxic capacities and immuno-
logic control. However, there are several lines of evidence that suggest
that cytotoxic capacity is not just an effect of reduced levels of viral repli-
cation. CD8+ T-cell proliferative and cytotoxic capacities are not restoredwhen HIV RNA levels are suppressed by potent antiretroviral therapy
(Migueles et al., 2009). In the rhesusmacaquemodel, infection of animals
carrying protective alleles with a cloned, highly pathogenic SIV common-
ly results in nonprogressive infection and control of SIV replication that is
largely removed by CD8+ T-cell depletion (Friedrich et al., 2007). While
these lines of evidence support that highly functional virus-speciﬁc
CD8+T cells are not simply an effect of reduced viremia, proof of causality
would require control of virus replication following passive transfer of
cells with intact proliferative and cytotoxic capacities into humans or an-
imal models.
Finally, the ﬁnding that a protective or weakly protective HLA allele
is not a requirement to develop high-level restriction of viral replication
57S.A. Migueles et al. / EBioMedicine 2 (2015) 46–58has some implications for efforts to harness the cellular immune
response in vaccines or immunotherapies. Induction of a response
capable of mediating immunologic control in diverse populations
would therefore not be conﬁned to those expressing HLA molecules
capable of presenting critical peptide epitopes. Considering that 25
distinct “weakly” protective or non-protective HLA proteins restricted
almost 40 immunodominant CD8+ T-cell responses of the B*57/27neg
LTNP/EC in the present study, the overall probability of carrying at
least one of these alleles in the general population is quite high.
Targeting the speciﬁcities dictated by HLA is therefore a much lower
barrier for the cellular immune response to overcome in the setting of
vaccines and immunotherapies than previously thought.
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